NYSE$EBS
Emergent BioSolutions Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Emergent BioSolutions' financial position strengthened in Q3 2024, marked by increased revenue, net income, and adjusted EBITDA, and the company raised its FY 2024 guidance.
Emergent BioSolutions reported a strong Q3 2024 with a 9% increase in total revenues to $293.8 million and a 144% increase in net income to $114.8 million compared to the prior year. Adjusted EBITDA also saw a significant rise of 432% to $105.3 million. The company has raised its full-year 2024 guidance, reflecting improved financial performance and strategic progress.
- Total revenues for Q3 2024 increased by 9% year-over-year, reaching $293.8 million.
- Net income for Q3 2024 saw a substantial increase of 144% compared to the previous year, amounting to $114.8 million.
- Adjusted EBITDA for Q3 2024 increased by 432% year-over-year, totaling $105.3 million.
- The company raised its full-year 2024 financial guidance, indicating improved expectations for future performance.
Headline financials
Revenue & EPS history
Emergent BioSolutions · Revenue · Quarterly
$294M
Revenue by segment
Emergent BioSolutions · $108M total across 3 segments · Q3 2023
- Other Products$50.1M+99.6%46.5%
- Anthrax MCM$32.9M—30.5%
- Smallpox MCM$24.7M—22.9%
Forward guidance
Emergent BioSolutions updated its financial forecast for full year 2024, anticipating total revenues between $1,065 million and $1,125 million, a net loss between $(203) million and $(183) million, adjusted EBITDA between $180 million and $200 million, and total segment adjusted gross margin between 43% and 45%.
Tailwinds
- Total revenues are projected to be between $1,065 million and $1,125 million.
- Adjusted EBITDA is expected to range from $180 million to $200 million.
- Total segment adjusted gross margin is forecasted to be between 43% and 45%.
- R&D expenditure is estimated to be approximately 7% of revenue.
- Capital expenditures are projected to be around $25 million.
Headwinds
- Net loss is forecasted to be between $(203) million and $(183) million.
- Adjusted net loss is projected to be between $(50) million and $(30) million.
- Interest expense is expected to be approximately $75 million.
- Depreciation and amortization are estimated to be around $109 million.
- Commercial Products revenue is expected to be between $420 million and $430 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-0.5%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-1.0%
Avg return
30 days after
47%
30 / 64 earnings
Positive
+75.5%
Q1 2024
Best reaction
-41.2%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.0% | +13.3% | +13.5% | |
| Q4 2025 | -27.1% | -21.0% | -28.6% | |
| Q3 2025 | +36.9% | +7.3% | +18.8% | |
| Q1 2025 | +35.0% | +24.1% | +39.9% | |
| Q4 2024 | -6.4% | -15.5% | -29.3% | |
| Q3 2024 | +22.8% | +33.6% | +0.6% | |
| Q2 2024 | -41.2% | -27.1% | -21.5% | |
| Q1 2024 | +75.5% | +111.7% | +203.2% | |
| Q4 2023 | -18.8% | -17.9% | -32.8% | |
| Q3 2023 | -8.9% | -22.9% | +5.5% | |
| Q2 2023 | -20.0% | -25.9% | -40.9% | |
| Q1 2023 | +18.5% | +0.7% | -8.0% | |
| Q4 2022 | -9.7% | -15.0% | -31.8% | |
| Q3 2022 | -36.7% | -22.5% | -38.6% | |
| Q2 2022 | -12.6% | -8.6% | -30.7% | |
| Q1 2022 | -11.2% | -8.5% | -3.4% | |
| Q4 2021 | -6.7% | -2.2% | +4.1% | |
| Q3 2021 | -37.0% | -33.3% | -20.3% | |
| Q2 2021 | +1.1% | -2.7% | -1.5% | |
| Q1 2021 | -1.7% | -4.8% | -2.3% | |
| Q4 2020 | -15.9% | -23.7% | -25.7% | |
| Q3 2020 | -6.1% | -10.9% | -15.8% | |
| Q2 2020 | +18.1% | +30.1% | +24.8% | |
| Q1 2020 | +6.4% | +7.5% | +12.9% | |
| Q4 2019 | +2.1% | -7.2% | -23.6% | |
| Q3 2019 | -5.4% | -7.6% | -5.4% | |
| Q2 2019 | +1.5% | +0.7% | -0.8% | |
| Q1 2019 | -8.0% | -9.2% | -23.7% | |
| Q4 2018 | -2.8% | -11.0% | -25.8% | |
| Q3 2018 | +6.0% | +12.6% | +19.0% | |
| Q2 2018 | +3.9% | +0.2% | +13.8% | |
| Q1 2018 | -4.0% | -4.9% | +1.4% | |
| Q4 2017 | -3.0% | +0.6% | +6.6% | |
| Q3 2017 | +7.0% | -3.6% | +9.1% | |
| Q2 2017 | -1.1% | -1.2% | +4.2% | |
| Q1 2017 | -3.5% | +3.2% | +5.6% | |
| Q4 2016 | +0.1% | +4.9% | -3.7% | |
| Q3 2016 | +9.8% | +22.0% | +4.7% | |
| Q2 2016 | -2.1% | -2.6% | -11.6% | |
| Q1 2016 | +0.9% | — | — | |
| Q4 2015 | -3.8% | — | — | |
| Q3 2015 | +2.5% | — | — | |
| Q2 2015 | +5.2% | — | — | |
| Q1 2015 | -2.0% | — | — | |
| Q4 2014 | -3.6% | — | — | |
| Q3 2014 | +7.6% | — | — | |
| Q2 2014 | -2.6% | — | — | |
| Q1 2014 | -10.5% | — | — | |
| Q4 2013 | +9.1% | — | — | |
| Q3 2013 | +9.1% | — | — | |
| Q2 2013 | +1.6% | — | — | |
| Q1 2013 | -5.0% | — | — | |
| Q4 2012 | +1.8% | — | — | |
| Q3 2012 | +8.4% | — | — | |
| Q2 2012 | +1.1% | — | — | |
| Q1 2012 | +4.9% | — | — | |
| Q4 2011 | +4.6% | — | — | |
| Q1 2011 | +4.6% | — | — | |
| Q4 2009 | +8.1% | — | — | |
| Q3 2011 | -5.3% | — | — | |
| Q3 2010 | -5.3% | — | — | |
| Q2 2010 | -8.2% | — | — | |
| Q2 2011 | -8.2% | — | — | |
| Q1 2010 | -1.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro